Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

ruxolitinib 1calcipotriene 1RXDX-106 1Pyrimethamine 1Dimethyl Sulfoxide 1Ascorbic Acid 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Squamous Cell × ruxolitinib × Clear all
NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

University of Pittsburgh

Phase EARLY_PHASE1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡